PV24 Speakers

Subject to change.

 

 

image

Michael Rivers

VP/Lifecycle Leader, Roche Digital Pathology, Roche

Michael joined Roche Diagnostics in 2006 and has been Lifecycle Leader for Digital Pathology since October 2015. In this role, he leads the Digital Pathology team in Santa Clara, California to develop and commercialize the Digital Pathology portfolio of products and technology for Roche. Michael also is a Past President of the Digital Pathology Association and has been a member of the DPA Board of Directors since 2015. Michael has held a number of sales and marketing leadership roles at Roche and is passionate about the opportunity to transform cancer diagnostics with Digital Pathology. 

 

 

SESSIONS

[Breakfast Sponsored by Roche] Challenges and Progress in Digital Pathology and Precision Oncology: An interactive Forum
   Tue, Nov 5
   07:30AM - 08:30AM ET
  Regency R

This workshop is an interactive session to discuss Digital Pathology challenges and progress. Experience with implementation and workflow vary, and topics like infrastructure, standardization, storage, interoperability, reimbursement, and regulatory, continue to be top of mind for those digitizing slides. To realize the value this technology can bring, we look forward to the exchange of information & accelerating access to high quality AI-assisted Digital Pathology.
Reimbursement TF Update: Setting the Stage for DP and AI Reimbursement
   Tue, Nov 5
   10:45AM - 11:30AM ET
  Regency R

Learning Objectives

  1. Understand the key priorities/activities of the DPA reimbursement task force.
  2. Better understand the current and evolving reimbursement landscape for DP and AI.
  3. Gain awareness of how the DPA is working with allied organizations to move reimbursement for DP and AI forward.

 

 

While digital pathology adoption is increasing and AI image analysis continues to show impressive potential to impact the practice of pathology, the overall return on investment (ROI) for digital pathology implementation remains a significant challenge. With an increasing number of DP solutions being cleared by the FDA for IVD applications, the lack of reimbursement is quickly becoming the most significant barrier to DP adoption.

Category III codes introduced in 2023 for tracking of whole slide imaging have been difficult to implement and may not be generating the evidence required to move forward quickly with significant change. Furthermore, to date, these codes are focused solely on digitization in the lab and do not provide for tracking or reimbursement for emerging AI image analysis solutions developed for digital pathology. 

The DPA Reimbursement Task Force has a mission to "Define and shape the pathway to reimbursement for digital pathology solutions enabling broad market access and delivery of value to patients and stakeholders." To this end, we have identified key strategic initiatives to enable the DPA to play a leading role in advocacy for a pathway to reimbursement for AI solutions. In addition, the task force is working through blog posts and webinars to educate the DPA members on the current state of reimbursement for DP and the opportunities ahead. 

This session will provide an update on the key work of the task force and provide a detailed look into the framework for DP AI reimbursement that the task force is pursuing.

 

Chat bot